Press release - for immediate release
15 June 2016
Sartorius Stedim Biotech launches innovative ambr® 250 modular bioreactor system
Sartorius Stedim Biotech (SSB) today introduced the ambr® 250 modular, an innovative benchtop mini bioreactor system for parallel fermentation or cell culture. This system combines a unique single-use bioreactor vessel and expandable system design to offer bioprocess scientists access to advanced benchtop bioreactor technology for process development.
The new system consists of a workstation with 2, 4, 6 or 8 single-use bioreactors, with a working volume range of 100 to 250 mL. These mini bioreactors, (based on the same stirred tank bioreactors in the well-established ambr® 250 high throughput system), contain impellers suitable for fermentation or cell culture and show excellent scale up to larger bioreactors. They are also fully integrated with liquid reservoirs and syringe pumps, allowing rapid experimental set up and turn around, thus significantly increasing lab efficiency.
The ambr 250 modular system brings simplicity to the lab bench. By following three easy steps a bioreactor and all the required accessories can be connected in just a couple of minutes. Once installed, the bioreactor has the process services for parameter control, including pH, DO, temperature or agitation. Additionally, feeds can now be delivered with high accuracy from the reagent reservoirs via the syringe pumps into the bioreactor. One control unit is capable of controlling up to eight bioreactor stations independently via an easy to use touch screen user interface.
Mwai Ngibuini, ambr 250 Product Manager, at SSB states: “Our new ambr 250 modular provides an excellent single-use platform, which enables rapid process development and optimization for scale-up to larger bioreactors such as BIOSTAT® pilot and manufacturing scale bioreactors. Utilizing this single-use workflow, will allow bioprocess scientists to improve productivity in their scalable bioprocess development and reduce development time lines, ensuring production of industrial enzymes, biologics and vaccines is more cost-efficient.”
For further information, please contact: